// App-Quantinova.ai

3605 : A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Researchers

Presenter

  • Richard Sposto

Principal Investigators

  • Jeannette Cassar

  • Guy Gammon

  • Daniel Magoon

  • Colleen E. Annesley

  • Patrick Brown

  • Elena Eckroth

  • Jemily Malvar

  • Paul Gaynon

  • Steven DuBois

  • Bill H Chang

  • Lia Gore

  • Keith J. August

  • Blythe Thomson

Medical Centers

  • Department of Pediatrics, Division of Neonatology, Childrens Hospital Los Angeles, Los Angeles, CA

  • Seattle Childrens Hospital, Seattle, WA

  • University of California, San Francisco, CA

Locations

  • United States

Companies

  • Ambit Biosciences In

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Acute Leukemia

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

  • Platelet-derived growth factor receptor

  • Colony stimulating factor 1 receptor

  • Hepatocyte growth factor receptor

  • Ret Proto-Oncogene

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

Drug/Treatment

  • Cytarabine liposomal

  • Etoposide

  • Etoposide phosphate

  • L-Tyrosine

  • lipase

  • AC220

Outcome

  • N/A

Study Design

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved